Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.67 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.63 |
| ▸ | LTA4H | P09960 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.51 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3570082 | 0.98 | KEAP1 (0.65) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| Hydrochloric Acid SCHEMBL56159 | 0.98 | KEAP1 (0.65) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| SCHEMBL188971 | 0.90 | KDM4E (0.69) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| SCHEMBL14547108 | 0.89 | KEAP1 (0.54) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| SCHEMBL3367452 | 0.88 | KDM4E (0.70) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| Hydrochloric Acid SCHEMBL3657036 | 0.88 | KDM4E (0.67) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| SCHEMBL2022333 | 0.88 | KCNH2 (0.56) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| SCHEMBL27750471 | 0.86 | KEAP1 (0.51) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| SCHEMBL12156398 | 0.86 | TDP1 (0.53) | KEAP1NFE2L2HRH3LTA4HTDP1 | |
| Hydrochloric Acid SCHEMBL5159771 | 0.86 | KCNH2 (0.54) | KEAP1NFE2L2HRH3LTA4HTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282995-B1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-08-26 | — | — | EP | claimed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | claimed |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | claimed |
| US-7297693-B2 | Nitrogen-containing heterocyclic compounds and their use as Raf inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-11-20 | — | — | US | claimed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | claimed |
| EP-1432702-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS RAF INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-16 | — | — | EP | claimed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | claimed |
| US-20040209883-A1 | Nitrogen-containing heterocyclic compounds and their use as raf inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-21 | — | — | US | claimed |
| EP-1326831-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2003-07-16 | — | — | EP | claimed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | claimed |
| WO-2002020480-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4716593-A2 | MIXED MODE SUBTRACTIVE ANION EXCHANGE CHROMATOGRAPHY LIGANDS BASED ON 4-(2-(DIMETHYLAMINO)ETHOXY)ANILINE STRUCTURES | Bio-Rad Laboratories, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4716593-A2 | MIXED MODE SUBTRACTIVE ANION EXCHANGE CHROMATOGRAPHY LIGANDS BASED ON 4-(2-(DIMETHYLAMINO)ETHOXY)ANILINE STRUCTURES | Bio-Rad Laboratories, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| CN-121263398-A | Mixed mode subtractive anion exchange chromatography ligands based on 4- (2- (dimethylamino) ethoxy) aniline structures | 生物辐射实验室股份有限公司 | 2026-01-02 | — | — | CN | disclosed |
| US-4344879-A | Quaternary and basic azamethine compounds and their use as colorants | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-08-17 | — | — | US | disclosed |
| EP-0029136-A2 | Quaternary and basic azomethine compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-05-27 | — | — | EP | disclosed |
| US-4247337-A | STABILIZED AGAINST FLOCCULATION BY ADDITION OF A PHENYLAMINOSULFONYL DERIVATIVE OF PHTHALOCYANINE | CIBA-GEIGY CORPORATION (US) | 1981-01-27 | — | — | US | disclosed |
| US-3994900-A | 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones | E. R. SQUIBB & SONS, INC. (US) | 1976-11-30 | — | — | US | disclosed |
| US-3875215-A | Substituted phenoxyalkyl quaternary ammonium compounds | DOW CHEMICAL CO | 1975-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | KEAP1 2073/4885NFE2L2 3808/4885HRH3 1940/4885 |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NPSR1, GABRE, CHRNE | KEAP1 4109/4885NFE2L2 3357/4885HRH3 235/4885 |
| US-20040209883-A1 | Nitrogen-containing heterocyclic compounds and their use as raf inhibitors | BRAF, RAF1, NPR1 | KEAP1 355/4885NFE2L2 1418/4885HRH3 1027/4885 |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | HTR1A, GABRA1, GABRE | KEAP1 4263/4885NFE2L2 3283/4885HRH3 269/4885 |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | KEAP1 4109/4885NFE2L2 3357/4885HRH3 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.